Bone marrow derived mesenchymal stem cells ameliorate inflammatory response in an in vitro model of familial hemophagocytic lymphohistiocytosis 2.
Handan Sevim AkanYusuf Çetin KocaefeMehmet Ali OnurDuygu Uçkan-ÇetinkayaÖzer Aylin GürpınarPublished in: Stem cell research & therapy (2018)
This study shows the ameliorating effect of MSCs as an adjuvant immune modulator toward the therapy of FHL2 patients. MSCs are supportive therapy candidates for FHL2 patients under circumstances where prolonged immunosuppression is required to gain time before allogeneic hematopoietic stem cell transplantation.
Keyphrases
- end stage renal disease
- inflammatory response
- bone marrow
- allogeneic hematopoietic stem cell transplantation
- mesenchymal stem cells
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- early stage
- acute lymphoblastic leukemia
- stem cells
- lipopolysaccharide induced
- umbilical cord
- lps induced